Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Renal Impairment Clinical Trial

Official title:

A Single Dose, Non-Randomized, Open-Label, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of AZD9977 in Participants With Renal Impairment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04469907
• Other study ID #: D6401C00008
• Status: Completed
• Phase: Phase 1
• Start date: June 22, 2020
• Est. completion date: October 28, 2021

Study information

• Verified date: March 2022
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single dose, non-randomized, open-label, parallel group study. The study will be conducted in participants with severe renal impairment and compared with matched participants with normal renal function. The duration of the study for an individual participant from Screening to Follow-up will be approximately 5 weeks.

Description:

The study will have 4 cohorts, consisting of participants with severe renal impairment who are not on dialysis (Cohort 1), moderate renal impairment (Cohort 2), mild renal impairment (Cohort 3) and participants with normal renal function (Cohort 4). Following completion of Cohort 1 and Cohort 4, pharmacokinetics (PK) and safety data will be reviewed and a decision will be made whether to study unmatched participants with moderate and mild renal impairment (Cohorts 2 and 3, respectively). Participants will be screened up to 21 days before administration of study drug. Eligible participants will be admitted to the clinical unit either on the evening of Day -2 or on the morning of Day -1. Each participant will receive a single oral dose of the study drug under fasted conditions on Day 1. Participants will be required to remain resident in the clinical unit until the morning of Day 3 but, if participants prefer, may also remain resident until all PK and other study procedures are completed on Day 7. This decision to extend residency will be made at the discretion of the principal investigator. If participants do check out on Day 3, participants will then return to the unit, as scheduled, for collection of PK samples and safety assessments, with a final Follow-up Visit on Day 14.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: October 28, 2021
• Est. primary completion date: October 28, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

Healthy matched control participants only (Cohort 4):

1. Participants who are overtly healthy.

2. Stable renal function, with eGFR of = 90 mL/min/1.73m^2.

Renally impaired participants only (Cohorts 1-3):

3. Participants who have renal impairment:

1. Cohort 1 participants with severe renal impairment must have an eGFR lesser than 30 mL/min/1.73m^2 not on dialysis

2. Cohort 2 participants with moderate renal impairment must have an eGFR of greater than or equal to 30 to lesser than 60 mL/min/1.73m^2

3. Cohort 3 participants with mild renal impairment must have an eGFR of greater than or equal to 60 to lesser than 90 mL/min/1.73m^2.

All participants (Cohorts 1-4):

4. Body weight of at least 50 kg and BMI within the range greater than or equal to 18 to lesser than or equal to 35 kg/m^2.

5. Male or female of non-childbearing potential.

6. Male participants should not donate sperm for the duration of the study.

7. Female participants must have a negative pregnancy test at time of study entry.

8. Capable of giving signed informed consent. Exclusion Criteria:

Healthy matched control participants only (Cohort 4):

1. Evidence of clinically significant cardiovascular, hematological, renal, endocrine, pulmonary, gastrointestinal, hepatic, neurologic, psychiatric, inflammatory or allergic disease.

Renally impaired participants only (Cohorts 1-3):

2. Renal transplant participants, participants on dialysis and those with a history of acute kidney injury.

All participants (Cohorts 1-4):

3. Any positive result on Screening for serum hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus antibody.

4. Known history of drug or alcohol abuse.

5. History of QT prolongation and arrhythmia.

6. Any moderate or potent inhibitors or inducers of CYP3A4.

7. Participants with a known hypersensitivity to AZD9977 or any of the excipients of the product.

8. For women only - currently pregnant or breast-feeding.

9. A positive local diagnostic test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening, clinical signs and symptoms consistent with COVID-19, or the patient has been previosuly hospitalised with COVID-19 infection.

Related Conditions & MeSH terms

• Renal Impairment
• Renal Insufficiency

Intervention

Drug:
• AZD9977
Participants will receive a single oral dose of AZD9977 under fasted conditions.

Locations

Country	Name	City	State
United States	Research Site	Blue Ash	Ohio
United States	Research Site	DeLand	Florida
United States	Research Site	Hialeah	Florida
United States	Research Site	Jacksonville	Florida
United States	Research Site	Northridge	California
United States	Research Site	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum observed plasma concentration (Cmax)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Area under the plasma concentration-time curve from time zero to infinity (AUC)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC0-t)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Time to reach maximum observed plasma concentration (tmax)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Half-life associated with terminal slope of a semi-logarithmic concentration time curve (t½?z)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Terminal elimination rate constant (?z)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Apparent total body clearance of drug from plasma after oral administration (CL/F)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Non-renal clearance of drug from plasma after oral administration (CLNR/F)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Apparent volume of distribution during the terminal phase after oral administration (Vz/F)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Mean residence time (MRT)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
Primary	Renal clearance of the drug from plasma (CLR)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post-dose)
Primary	Cumulative amount of unchanged drug excreted into the urine (Ae)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post-dose)
Primary	Fraction of the drug excreted into the urine (fe)	To assess the PK of AZD9977 following administration of AZD9977	Day 1 to 3 (Pre-dose, 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post-dose)
Secondary	Number of participants with adverse events and serious adverse events	To evaluate the safety and tolerability of AZD9977	Day -2 to Day 14
Secondary	Estimated Glomerular Filtration Rate (eGFR)	To determine eGFR based on creatinine and cystatin C using CKD-EPI formula	Screening, Day -1, Day 1 to 3 (Pre-dose, 4, 12, 24 , 36, and 48 hours)